天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數據庫列表>64821-19-8

64821-19-8

中文名稱 化合物MAO-IN-M30二鹽酸鹽
英文名稱 VAR10300 dihydrochloride
CAS 64821-19-8
分子式 C14H16Cl2N2O
分子量 299.196
MOL 文件 64821-19-8.mol
更新日期 2025/01/12 18:03:34
64821-19-8 結構式 64821-19-8 結構式

基本信息

中文別名
化合物MAO-IN-M30二鹽酸鹽
英文別名
M30 dihydrochloride
M-30 dihydrochloride
VAR10300 dihydrochloride
MAO-IN-M30 dihydrochloride
5-[[Methyl(2-propyn-1-yl)amino]methyl]-8-quinolinol Dihydrochloride
5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline dihydrochloride
N-(8-Hydroxy-5-quinolylmethyl)-N-methyl-2-propynylamine dihydrochloride

物理化學性質

儲存條件2-8°C
溶解度DMSO、庚烷和二甲苯:≥21mg/mL
形態(tài)粉末
顏色黃綠色
水溶解性溶于水至100mM

安全數據

危險性符號(GHS)GHS hazard pictogramsGHS hazard pictograms
GHS05,GHS07
警示詞危險
危險性描述H302-H318
危險品標志Xn
危險類別碼22-41
安全說明26-39
WGK Germany3

常見問題列表

生物活性
MAO-IN-M30 dihydrochloride 是一種口服活性,可通過血腦屏障的,腦選擇性不可逆 MAO-A (IC50=37 nM) 和 MAO-B (IC50=57 nM) 抑制劑。MAO-IN-M30 dihydrochloride 是有效的鐵螯合劑、自由基清除劑。MAO-IN-M30 dihydrochloride 對 Dexamethasone 誘導的腦細胞凋亡具有神經保護作用。MAO-IN-M30 dihydrochloride 在 MPTP 和 lactacystin 帕金森病模型中也顯示出神經恢復活性。
靶點

MAO-A

37 nM (IC 50 )

MAO-B

57 nM (IC 50 )

體外研究

MAO-IN-M30 (0.25 nM; 72 hours) significantly increased cell viability to ~90% after exposure to Dexamethasone.
MAO-IN-M30 (0-10 μM; 24 hours) enhances PC12 cell survival.
MAO-IN-M30 treatment significantly decreases the occurrence of fragmented DNA compared to the dexamethasone-treated group in SH-SY5Y cells.

Cell Viability Assay

Cell Line: SH-SY5Y cells
Concentration: 0.25?nM
Incubation Time: 72 hours
Result: Significantly increased cell viability to ~90% after exposure to Dexamethasone.

Cell Viability Assay

Cell Line: PC12 cells
Concentration: 0-10 μM
Incubation Time: 24 hours
Result: Enhanced the PC12 cell viability, the cell viability increasing to 85 ± 6 and 90 ± 7%.
體內研究

MAO-IN-M30 (0.5-2.5 mg/kg; p.o.; once daily for 14 consecutive days) possesses neuroprotective activities.

Animal Model: Male C57/BL mice (20-22 g; MPTP-induced neurotoxicity in mice)
Dosage: 0.5, 2.5 mg/kg
Administration: P.o.; once daily for 14 consecutive days
Result: Significantly elevate striatal dopamine levels, reduce its metabolism, and elevate tyrosine-hydroxylase protein levels and activity. Elevated MPTP-reduced dopaminergic and transferrin receptor cell count in the SNpc.
"64821-19-8" 相關產品信息